Waiting for JAK inhibitor safety data

The US Food and Drug Administration (FDA) has recently added a new ‘black box warning’ on all currently approved Janus kinase (JAK) inhibitors indicated for the treatment of arthritis and other inflammatory conditions based on results from the ORAL Surveillance study of tofacitinib versus tumour nec...

Descripción completa

Detalles Bibliográficos
Autores principales: Kragstrup, Tue Wenzel, Glintborg, Bente, Svensson, Annemarie L, McMaster, Christopher, Robinson, Philip C, Deleuran, Bent, Liew, David FL
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Treatments
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867353/
https://www.ncbi.nlm.nih.gov/pubmed/35197363
http://dx.doi.org/10.1136/rmdopen-2022-002236

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867353/
https://www.ncbi.nlm.nih.gov/pubmed/35197363
http://dx.doi.org/10.1136/rmdopen-2022-002236

Ejemplares similares